Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00134511
Status:
COMPLETED
Last Update Posted:
2007-11-07
First Post:
2005-08-22
Brief Title:
Study To Evaluate The Effect Of TorcetrapibAtorvastatin In Patients With Genetic High Cholesterol Disorder
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 3 Multi-Center Open Label Forced Titration Study To Evaluate The Efficacy Safety And Tolerability Of TorcetrapibAtorvastatin Combination Administered Orally Once Daily Qd In Patients With Homozygous Familial Hypercholesterolaemia
Status:
COMPLETED
Status Verified Date:
2006-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Torcetrapib project was terminated on December 2 2006 due to safety findings
To evaluate the efficacy and safety of the lipid drug Torcetrapibatorvastatin in patients with genetically known disorder of extremely high cholesterol
To evaluate the efficacy and safety of the lipid drug Torcetrapibatorvastatin in patients with genetically known disorder of extremely high cholesterol
Detailed Description:
For additional information please call 1-800-718-1021
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None